NCT03631641View on ClinicalTrials.gov

Nivolumab in Preventing Colon Adenomas in Participants With Lynch Syndrome and a History of Partial Colectomy

PHASE2TerminatedINTERVENTIONAL

Enrollment

3

Participants

Timeline

Start Date

October 4, 2018

Primary Completion Date

January 25, 2021

Study Completion Date

January 25, 2021

Conditions

Colon AdenomaColon CarcinomaLynch SyndromeMLH1 Gene MutationMSH2 Gene Mutation

Interventions

BIOLOGICAL

Nivolumab

Given IV

Trial Locations (1)

43210

Ohio State University Comprehensive Cancer Center, Columbus

Sponsors

Collaborators (1)

Bristol-Myers Squibb

All Listed Sponsors

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

John Hays

OTHER